VICENTE VICENTE, M.D.; IGNACIO ALBERCA, M.D.; ROGELIO GONZALEZ, M.D.; ADRIAN ALEGRE, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Recently, de la Fuente and coworkers (1) confirmed that intravenous administration of desmopressin to persons with mild or moderate hemophilia is useful in the management of hemorragic episodes. In a previous study (2) we have shown that a significant increase of procoagulant activity of factor VIII (FVIII:C) can be obtained after a single standard dose of intranasal desmopressin (260 µg) in persons with mild hemophilia and in healthy persons.
In view of such findings, we have treated 11 patients with mild hemophilia (basal values of VIII:C, 5 to 25 U/dL) with a single dose (260 µg) of
VICENTE V, ALBERCA I, GONZALEZ R, et al. Intranasal Desmopressin in Mild Hemophilia A. Ann Intern Med. 1985;103:807–808. doi: https://doi.org/10.7326/0003-4819-103-5-807
Download citation file:
Published: Ann Intern Med. 1985;103(5):807-808.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use